St. Gallen's Recommendations May Impact Adoption of Leading Breast Cancer Genetic Tests
July 08, 2009
St. Gallen's Recommendations May Impact Adoption of Leading Breast Cancer Genetic Tests
The recommendations by the expert group, which met in Switzerland in March and involves healthcare leaders from around the world, could impact the reimbursement and adoption of breast cancer genetic tests, such as Agendia's MammaPrint and Genomic Health's Oncotype DX.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- MDx Highlights from the American Society of Clinical Oncology's 2012 Meeting
June 13, 2012 / Pharmacogenomics Reporter - Clarient's Mammostrat to Enter Breast Cancer Recurrence Market as LDT by Fourth Quarter
July 14, 2010 / Pharmacogenomics Reporter - Agendia Hoping Fourth FDA Clearance for MammaPrint Convinces Payors
December 23, 2009 / Pharmacogenomics Reporter - CMS Stance on Reimbursement of Multi-Analyte Algorithm Assays Raises Industry Concerns
September 19, 2012 / Pharmacogenomics Reporter - AMA Proposes New Coding Criteria for Multi-Analyte Algorithm-Based Tests
November 9, 2011 / Pharmacogenomics Reporter